drugset / Trial / NCT04548427

Study to Evaluate the Efficacy and Safety of CKD-352

NCT04548427

Phase 3 Completed 283 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of CKD-352 in patients with dry eye disease

Timeline

Start
2020-09-22
Primary completion
2021-05-07
Completion
2021-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-352 Unknown Other
Comparator Diquafosol Oligonucleotide (other) 3 % Other

Indications